Live Yum Brands Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ORAMED PHARMACEUTICALS INC.

Get SEC filing alerts via email and in your feed for ORAMED PHARMACEUTICALS INC.

ORMP

ORAMED PHARMACEUTICALS INC.

About ORAMED PHARMACEUTICALS INC.

Oramed Pharmaceuticals develops innovative oral drug delivery solutions, primarily focusing on oral insulin and proteins for diabetes and other conditions. Its core business involves research, clinical trials, and strategic partnerships to commercialize oral biologic therapies. The company owns extensive intellectual property, collaborates with global partners, and targets markets worldwide, aiming to improve patient convenience and treatment efficacy through proprietary technology and strategic licensing.
This description was generated via AI from an annual report. Updated 10 months ago.

Latest SEC Filings from ORAMED PHARMACEUTICALS INC.

1
1
ORAMED PHARMACEUTICALS INC. Oramed Pharmaceuticals Reports $38.3 Million Net Income Turnaround in Latest Quarterly Filing

Via official filing (AI summary) | 2 months ago | 0 comments

2
1
ORAMED PHARMACEUTICALS INC. Oramed Pharmaceuticals Reports $64 Million Net Income and Revenue Growth for Fiscal Year 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
ORAMED PHARMACEUTICALS INC. Oramed Pharmaceuticals Reports $2M Revenue and $54M Net Income for Quarter Ending September 30, 2025

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
ORAMED PHARMACEUTICALS INC. Oramed Pharmaceuticals Reports $2 Million Revenue in Q2 2025, Net Income Declines

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
ORAMED PHARMACEUTICALS INC. Oramed Pharmaceuticals Reports $2 Million Revenue in Q1 2025, Net Loss of $7.6 Million

Via official filing (AI summary) | about 1 year ago | 0 comments